Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin with IMRT for Elderly NPC
NCT06688175Phase 2Enrolling by invitation
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lobaplatin in nasopharyngeal carcinoma (NPC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Objective Response Rate at 6 months. Started Nov 2024; status: enrolling by invitation.
02
Drugs
lobaplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06688175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688175.